Insights into the impact of phenolic residue incorporation at each position along secretin for receptor binding and biological activity

Regulatory Peptides

Volumn 180, Issue 1, 2013, Pages 5-11

  Dong, Maoqing ^a   Pinon, Delia I ^a   Miller, Laurence J ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Alanine scanning; Benzoyl phenylalanine; Secretin; Structure activity relationship study

Indexed keywords

ALANINE; G PROTEIN COUPLED RECEPTOR; PHENOL DERIVATIVE; SECRETIN; SECRETIN DERIVATIVE; SECRETIN RECEPTOR; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; MOLECULAR SEQUENCE DATA; PHENOLS; PROTEIN BINDING; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; SECRETIN; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84871920402     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.10.001     Document Type: Article

References (30)

1. Adelhorst K., Hedegaard B.B., Knudsen L.B., Kirk O. Structure-activity studies of glucagon-like peptide-1. J Biol Chem 1994, 269:6275-6278.
2. Dong M., Le A., Te J.A., Pinon D.I., Bordner A.J., Miller L.J. Importance of each residue within secretin for receptor binding and biological activity. Biochemistry 2011, 50:2983-2993.
3. Igarashi H., Ito T., Hou W., Mantey S.A., Pradhan T.K., Ulrich C.D., Hocart S.J., Coy D.H., Jensen R.T. Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig. J Pharmacol Exp Ther 2002, 301:37-50.
4. Igarashi H., Ito T., Pradhan T.K., Mantey S.A., Hou W., Coy D.H., Jensen R.T. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors. J Pharmacol Exp Ther 2002, 303:445-460.
5. Nicole P., Lins L., Rouyer-Fessard C., Drouot C., Fulcrand P., Thomas A., Couvineau A., Martinez J., Brasseur R., Laburthe M. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem 2000, 275:24003-24012.
6. Dong M., Asmann Y.W., Zang M., Pinon D.I., Miller L.J. Identification of two pairs of spatially approximated residues within the carboxyl terminus of secretin and its receptor. J Biol Chem 2000, 275:26032-26039.
7. Dong M., Wang Y., Hadac E.M., Pinon D.I., Holicky E., Miller L.J. Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor. J Biol Chem 1999, 274:19161-19167.
8. Dong M., Wang Y., Pinon D.I., Hadac E.M., Miller L.J. Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the amino-terminal tail of the secretin receptor using photoaffinity labeling. J Biol Chem 1999, 274:903-909.
9. Mayo K.E., Miller L.J., Bataille D., Dalle S., Goke B., Thorens B., Drucker D.J. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003, 55:167-194.
10. Hoare S.R. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 2005, 10:417-427.
11. Dong M., Li Z., Pinon D.I., Lybrand T.P., Miller L.J. Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor. J Biol Chem 2004, 279:2894-2903.
12. Dong M., Lam P.C., Gao F., Hosohata K., Pinon D.I., Sexton P.M., Abagyan R., Miller L.J. Molecular approximations between residues 21 and 23 of secretin and its receptor: Development of a model for peptide docking with the amino terminus of the secretin receptor. Mol Pharmacol 2007, 72:280-290.
13. Dong M., Lam P.C., Pinon D.I., Hosohata K., Orry A., Sexton P.M., Abagyan R., Miller L.J. Molecular Basis of Secretin Docking to Its Intact Receptor Using Multiple Photolabile Probes Distributed throughout the Pharmacophore. J Biol Chem 2011, 286:23888-23899.
14. Dong M., Lam P.C., Pinon D.I., Orry A., Sexton P.M., Abagyan R., Miller L.J. Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment. J Biol Chem 2010, 285:9919-9931.
15. Dong M., Lam P.C., Pinon D.I., Sexton P.M., Abagyan R., Miller L.J. Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding. Mol Pharmacol 2008, 74:413-422.
16. Dong M., Li Z., Zang M., Pinon D.I., Lybrand T.P., Miller L.J. Spatial approximation between two residues in the mid-region of secretin and the amino terminus of its receptor. Incorporation of seven sets of such constraints into a three-dimensional model of the agonist-bound secretin receptor. J Biol Chem 2003, 278:48300-48312.
17. Dong M., Zang M., Pinon D.I., Li Z., Lybrand T.P., Miller L.J. Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus. Mol Endocrinol 2002, 16:2490-2501.
18. Zang M., Dong M., Pinon D.I., Ding X.Q., Hadac E.M., Li Z., Lybrand T.P., Miller L.J. Spatial Approximation between a Photolabile Residue in Position 13 of Secretin and the Amino Terminus of the Secretin Receptor. Mol Pharmacol 2003, 63:993-1001.
19. Gardner J.D., Conlon T.P., Beyerman H.C., Van Zon A. Interaction of synthetic 10-tyrosyl analogues of secretin with hormone receptors on pancreatic acinar cells. Gastroenterology 1977, 73:52-56.
20. 10] porcine secretin. Int J Pept Protein Res 1991, 37:185-190.
21. Powers S.P., Pinon D.I., Miller L.J. Use of N, O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. Int J Pept Protein Res 1988, 31:429-434.
22. Ulrich C.D., Pinon D.I., Hadac E.M., Holicky E.L., Chang-Miller A., Gates L.K., Miller L.J. Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors. Gastroenterology 1993, 105:1534-1543.
23. Munson P.J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980, 107:220-239.
24. Parthier C., Reedtz-Runge S., Rudolph R., Stubbs M.T. Passing the baton in class B GPCRs: peptide hormone activation via helix induction?. Trends Biochem Sci 2009, 34:303-310.
25. Neumann J.M., Couvineau A., Murail S., Lacapere J.J., Jamin N., Laburthe M. Class-B GPCR activation: is ligand helix-capping the key?. Trends Biochem Sci 2008, 33:314-319.
26. Bodansky M., Natarajan S., Gardner J.D., Makhlouf G.M., Said S.I. Synthesis and some pharmacological properties of the 23-peptide 15-lysine-secretin-(5-27). Special role of the residue in position 15 in biological activity of the vasoactive intestinal polypeptide. J Med Chem 1978, 21:1171-1173.
27. Gardner J.D., Rottman A.J., Natarajan S., Bodanszky M. Interaction of secretin5-27 and its analogues with hormone receptors on pancreatic acini. Biochim Biophys Acta 1979, 583:491-503.
28. Robberecht P., Conlon T.P., Gardner J.D. Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig. Structural requirements for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3':5'-monophosphate. J Biol Chem 1976, 251:4635-4639.
29. Dong M., Pinon D.I., Miller L.J. Development of a biologically active secretin analogue incorporating a radioiodinatable photolabile p-(4-hydroxybenzoyl)phenylalanine in position 10. Regul Pept 2002, 109:181-187.
30. Dong M., Wang Y., Miller L.J. Dual contacts between peptide agonist ligands and the secretin receptor directly established by photoaffinity labeling. Ann N Y Acad Sci 2000, 921:381-386.